The authors in [44], who previously showed that Gpr17 is a direct target of Olig2, demonstrated that Gpr17 is activated upon injury to OLs and that targeted inhibition of Gpr17 promotes OL remyelination, highlighting the therapeutic potential for Gpr17 in demyelinating diseases [44]. The gene discussed is OLIG2; the disease is demyelinating disease.